Amantadine News and Research

RSS

New AAN guideline recommends several treatments for people with Huntington's chorea

A new guideline released by the American Academy of Neurology recommends several treatments for people with Huntington's disease who experience chorea—jerky, random, uncontrollable movements that can make everyday activities challenging.

19 Jul 2012

Adamas to present update on Nurelin program at CHI Targeting Parkinson's Disease Symposium

Adamas Pharmaceuticals, Inc., a privately held company, announced today that it will present an update on its Nurelin (amantadine HCl extended release capsules) program at the Cambridge Healthtech Institute's (CHI) Targeting Parkinson's Disease Symposium being held today in Philadelphia.

4 Jun 2012

New tool to map extent of traumatic brain injury

Traumatic brain injury among soldiers, sportsmen and women and accident survivors are common but may go undetected at the time of the event and manifest later in life. Now scientists are testing a tool that lights up the breaks these injuries leave deep in the brain's wiring, much like X-rays show broken bones.

4 Mar 2012

Parkinson's drug Amantadine may help brain injury victims: Study

The study shows that Amantadine helps boost brain levels of dopamine, a neurotransmitter linked to arousal. And for patients who are in a vegetative state following a brain injury, the drug can help -- possibly by improving responsiveness during rehabilitation.

1 Mar 2012

Bird flu updates

The latest bird flu virus that killed a 39-year-old bus driver in the southern Chinese city of Shenzhen over the weekend is not yet transmissible between humans, Chinese health authorities said. The man, who lived in Shenzhen just across the border from Hong Kong, died from multi-organ failure on Saturday, a week after being admitted to hospital with a fever brought on by the virus, state media reported.

3 Jan 2012

Tamiflu resistant flu on the rise: Study

According to World Health Organization researchers there is a rise in Australia in the number of seasonal influenza cases resistant to Tamiflu, the most commonly used antiviral drug. The rise in such cases involving the pandemic 2009 A (H1N1) flu strain, also known as swine flu, took place during Australia's most recent winter: May through August of 2011.

2 Jan 2012

Romark announces results from NT-300 Phase 2B-3 trial on influenza

Romark Laboratories announced that results of a large Phase 2B-3 US clinical trial of its new flu drug, NT-300 (nitazoxanide), will be presented as an oral late-breaking communication at the 49th Annual Meeting of the Infectious Diseases Society of America (IDSA) being held in Boston, October 20-23, 2011.

22 Oct 2011

Adamas begins ADS-5102 Phase 2/3 clinical trial in Parkinson's disease

Adamas Pharmaceuticals, Inc., a privately held company, announced today that it has initiated a Phase 2/3 clinical trial of its proprietary investigational drug ADS-5102 (amantadine HCl extended release) for the treatment of levodopa induced dyskinesia (LID) in patients with Parkinson's disease.

28 Sep 2011

Combination therapies inhibiting P7 could prevent spread of HCV

British researchers have identified specific resistance mutations for two classes of p7 inhibitor, which may explain their lack of effectiveness in clinical trials combined with current standard of care.

29 Jun 2011

Researchers analyze drugs' efficiency on influenza A virus

Beating the flu has always been tough, but it has gotten even more difficult in recent years. Two of the four antiviral drugs used to treat a nasty case of the influenza A virus no longer work.

22 Oct 2010

New development in flu prevention & treatment

In a groundbreaking development, scientists at the Australian National University in Canberra have found the key to the mutation of the flu virus. This may allow the manufacturing of a life-long vaccine stopping the need for repeated vaccinations. The scientists reveal that they have found a protein in the virus that changes or mutates in order to develop resistance in the virus.

20 Jul 2010

Adamas Pharmaceuticals presents study results of TCAD therapy in immunocompromised influenza A patients

Adamas Pharmaceuticals, Inc., a privately held company, announced today the results from the first clinical study evaluating triple combination antiviral drug (TCAD) therapy for the treatment of influenza A in immunocompromised patients. Data from this Phase 1b study were presented by clinical investigator Dr. Janet Englund in a clinical symposium at the 23rd International Conference on Antiviral Research (ICAR) in San Francisco.

29 Apr 2010

TCAD therapy superior to double combinations and monotherapy against influenza viruses

Adamas Pharmaceuticals, Inc., a privately held company, announced today results from in vivo animal studies and in vitro tests demonstrating that its triple combination antiviral drug (TCAD) therapy is superior relative to double combinations and monotherapy against multiple strains of pandemic and avian influenza viruses. Results of these studies were presented Sunday evening in an oral session at the XII International Symposium on Respiratory Viral Infections being held in Taipei.

15 Mar 2010

TCAD therapy active and synergistic against drug resistant influenza virus strains

Adamas Pharmaceuticals, Inc., a privately held company, reported today on the publication of results from a preclinical study that demonstrated the synergistic effects of triple combination antiviral drug (TCAD) therapy against multiple strains of seasonal, pandemic, and avian influenza A (H1N1, H3N2 and H5N1) virus, including three strains of amantadine resistant pandemic H1N1 and two strains of oseltamivir resistant seasonal H1N1.

23 Feb 2010

Amantadine binds to and blocks critical M2 proton channel necessary for influenza virus to infect healthy cells

Antiviral drugs block influenza A viruses from reproducing and spreading by attaching to a site within a proton channel necessary for the virus to infect healthy cells, according to a research project led by Iowa State University's Mei Hong and published in the Feb. 4 issue of the journal Nature.

4 Feb 2010

EGCg in green tea inhibits flu infection

Joint research conducted by the Central Research Institute of ITO EN, Ltd. and Professor Takashi Suzuki of the School of Pharmaceutical Sciences, University of Shizuoka, showed that epigallocatechin gallate (EGCg), a kind of catechin contained in green tea, had an inhibitory effect against three types of influenza viruses, including the swine-origin H1N1 virus that caused pandemic flu in 2009, and that its effect did not depend on the type of virus. These findings once again suggest that green tea is effective in preventing flu.

24 Dec 2009

Grant of $1 million awarded to develop new treatments for dyskinesia

The Michael J. Fox Foundation for Parkinson's Research has awarded $1 million for a clinical study aiming to make a critical step toward the development of new treatments for dyskinesia, the excessive and uncontrollable movements that are a complication of long-term dopamine replacement therapy in patients with Parkinson's disease.

22 Dec 2009

Adamas Pharmaceuticals expands its Phase 2 TCAD therapy study for influenza A

Adamas Pharmaceuticals, Inc., a privately held company, announced today that it has expanded its Phase 2 clinical study of a proprietary investigational triple-combination antiviral drug therapy for influenza to include centers in the United States, Canada and Europe. The study, which was initiated in August 2009 in the Southern Hemisphere, is designed to investigate Adamas' triple combination antiviral drug (TCAD) therapy as a treatment for influenza A, including novel influenza A/H1N1, the cause of the current flu pandemic.

19 Nov 2009

Drug-cocktail approach offers hope in developing single agent to treat drug-resistant H1N1 swine flu

An experimental drug cocktail that includes three prescriptions now widely available offers the best hope in developing a single agent to treat drug-resistant H1N1 swine flu, says a virology researcher in the University of Alabama Birmingham (UAB) Division of Pediatric Infectious Diseases.

28 Oct 2009

TCAD therapy shows potency against seasonal and novel H1N1 influenza viruses

Adamas Pharmaceuticals, Inc., a privately held company, announced today that a multi-center in vitro study of its proprietary triple combination antiviral drug (TCAD) therapy showed substantially greater potency against seasonal and novel H1N1 influenza viruses than currently recommended single or double therapy and that the triple combination is active against drug-resistant flu strains.

14 Sep 2009